New Findings from University of Pittsburgh in the Area of Ovarian Cancer Described (Acetate Drives Ovarian Cancer Quiescence Via Acss2-mediated Acetyl-coa Production).

A recent study conducted at the University of Pittsburgh explores the role of the metabolic enzyme ACSS2 in driving quiescence in ovarian cancer cells. The research suggests that increased ACSS2 activity leads to a reversible cell cycle exit in ovarian cancer cells, potentially impacting therapeutic response to chemotherapies like platinum. The study highlights the importance of metabolic reprogramming in understanding ovarian cancer progression and treatment outcomes. [Extracted from the article]